NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Evaluation of a new antinauseant drug for the prevention of motion sicknessThe new drug, AHR 5645B, together with other drugs was evaluated in tests, conducted with eight male subjects, concerning its ability to prevent motion sickness. It was found that AHR 5645B, used in doses of 20, 50, and 100 mg, was not efficacious in preventing experimental motion sickness. A combination of 50 mg meclizine and 25 mg ephedrine sulfate produced the best results. Favorable results were also obtained with a combination of 12.5 mg promethazine hydrochloride and 12.5 mg ephedrine sulfate. The findings in the reported experiment point to the difficulty of identifying a highly efficacious antimotion sickness drug for everyone.
Document ID
19770066985
Acquisition Source
Legacy CDMS
Document Type
Reprint (Version printed in journal)
Authors
Graybiel, A.
(Naval Aerospace Medical Research Lab. Pensacola, FL, United States)
Knepton, J.
(U.S. Naval Aerospace Medical Center Aerospace Medical Research Laboratory, Pensacola, Fla., United States)
Date Acquired
August 9, 2013
Publication Date
September 1, 1977
Subject Category
Aerospace Medicine
Accession Number
77A49837
Funding Number(s)
CONTRACT_GRANT: NAVY TASK MF51,524,005-7015
CONTRACT_GRANT: NASA ORDER T-5904-B
Distribution Limits
Public
Copyright
Other

Available Downloads

There are no available downloads for this record.
No Preview Available